0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > VEGF165 > VE5-H8210

Biotinylated Human VEGF165 Protein, epitope tag free, ultra sensitivity, primary amine labeling

Order Now

  • Synonym
    RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF
  • Source
    Biotinylated Human VEGF165, epitope tag free, primary amine labeling(VE5-H8210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
    Predicted N-terminus: Ala 27
  • Molecular Characterization
    VEGF165 Structure

    This protein carries no "tag".

    The protein has a calculated MW of 19.2 kDa. The protein migrates as 23-25 kDa under reducing (R) condition, and 40-50 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Labeling
    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.
  • Protein Ratio
    Passed as determined by the HABA assay / binding ELISA.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 24 months in lyophilized state;
    2. -70°C for 24 months under sterile conditions after reconstitution.
SDS-PAGE
VEGF165 SDS-PAGE

Biotinylated Human VEGF165, epitope tag free, primary amine labeling on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
 VEGF165 ELISA

Immobilized human VEGFR1/R2, Fc Tag at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.4-3 ng/mL (QC tested).

 VEGF165 BATCH ELISA
 VEGF165 ELISA

Immobilized Anti-VEGF MAb,Human IgG1 (Avastin) at 5 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.2-4 ng/mL (Routinely tested).

 VEGF165 ELISA

Immobilized Human Neuropilin-1, His Tag (Cat. No. NR1-H5228) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.031-2 μg/mL (Routinely tested).

  • Background
    VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €250.00

Price(EUR) : €990.00

Recommended Products
Plaque enduite de streptavidine

Price(EUR) : €30.00

Price(EUR) : €140.00

Streptavidine-HRP

Price(EUR) : €50.00

Price(EUR) : €120.00

Billes magnétiques™ Streptavidine

Price(EUR) : €140.00

Price(EUR) : €230.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:40 Details
  • Number of Drugs in Clinical Trials:63 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message